Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
Jianqiu Wu(Jiangsu Cancer Hospital), Jifeng Feng(Zhejiang Cancer Hospital), Zuoxing Niu(Shandong Tumor Hospital), Jishi Wang(Guiyang Medical University), Li Xu(University of Reunion Island), Yu Hu(Wuhan Union Hospital), Tingchao Chen(Roche (China)), Yongping Song(First Affiliated Hospital of Zhengzhou University), Wei Li(Jilin University), Xiaohong Zhang(Harbin Engineering University), Mingzhi Zhang(Chinese Academy of Sciences), Xiaolin Li(Guangzhou University of Chinese Medicine), Wei Wang(Peking University), Ru Feng(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhen Xiao, Hai Bai(Lanzhou Army General Hospital), Weijing Zhang(307th Hospital of Chinese People’s Liberation Army), Changping Wu(Soochow University), Yongzhi Zhuang(Daqing Oilfield General Hospital), Tongjian Cui(Fujian Medical University), Liping Su, Yuhuan Gao(Hebei Medical University), Zhiyun Zhao(Roche (China)), Yingmin Liang(Tang Du Hospital), Zimin Sun(University of Science and Technology of China), Jiewen Peng(Zhongshan People's Hospital), Yun Zeng(Xidian University)
Cited by 32
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
|Molecular Cell|2007|731
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
|Science Immunology|2020|555